Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1993-05-20
1995-12-05
Robinson, Douglas W.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 2711, 536 41, C07H 302, C07H 508
Patent
active
054730635
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to the synthesis of novel chemical compounds and pharmaceutically acceptable salts thereof which can be used in therapy for hepatitis B virus, and also for treatment of other virus diseases, such as those of herpes viruses, diseases which include both common infections and neoplastic diseases, i.e. cancer.
BACKGROUND OF THE INVENTION
The effects of viruses on bodily functions is the end result of changes occurring at the cellular and subcellular levels. The pathogenic changes at the cellular level are different for different combinations of viruses and host cells. While some viruses cause a general destruction (killing) of certain cells, other may transform cells into a neoplastic state.
Important common viral infections are herpes dermatitis (including herpes labialis), herpes keratitis, herpes genitalis, herpes zoster, herpes encephalitis, infectious mononucleosis and cytomegalovirus infections all of which are caused by viruses belonging to the herpes virus group. Other important viral diseases are influenza A and B which are caused by influenza A and B virus, respectively. Another important common viral disease is viral hepatitis and especially hepatitis B virus infections are widely spread. Effective and selective antiviral agents are needed for treatment of these diseases as well as for other diseases caused by viruses.
Several different viruses of both DNA and RNA type have been shown to cause tumors in animals. The effect of cancerogenic chemicals can on animals result in activation of latent tumor viruses. It is possible that tumor viruses are involved in human tumors. The most likely human cases known today are leukemias, sarcomas, breast carcinomas, Burkitt lymphomas, nasophopharyngal carcinomas and cervical cancers where RNA tumor viruses and herpes viruses are involved. This makes the search for selective inhibitors of tumorogenic viruses and their functions an important undertaking in the efforts to treat cancer.
In the late seventies a new disease was reported, which subsequently was referred to as Acquired Immuno Deficiency Syndrome (AIDS). It is now generally accepted that a retrovirus referred to as HIV (Human Immunodeficiency Virus), formerly known as Human T-cell Lymphotrophic Virus (HTLV-III) or Lymphadenopathy Associated Virus (LAV) plays an essential role in the etiology of AIDS. Different types of HIV have been found, such as HIV-1 and HIV-2 and more are likely to be isolated.
AIDS is characterized by a profound immunodeficiency due to low numbers of a subset of lymphocyte-T-helper cells, which are one target for HIV infection. The profound immunodeficiency in AIDS patients makes these patients highly susceptible to a variety of opportunistic infections of bacterial, fungal, protozoal or viral etiology. The etiological agents among viral opportunistic infections are often found in the herpes virus group, i.e. herpes simplex virus (HSV), Varicella Zoster virus (VZV), Epstein-Barr virus (EBV) and, especially, cytomegalovirus (CMV). Other retroviruses affecting humans are HTLV-I and II and examples of retroviruses affecting animals are feline leukemia virus and equine infectious anaemia virus. Human diseases such as multiple sclerosis, psoriasis, tropical spastic paresis and Kawasaki disease have also been reported to be associated with retrovirus infections.
Hepatitis B virus infections cause severe disease such as acute hepatitis, chronic hepatitis, fulminant hepatitis in a considerable number of persons. It is estimated that there are 200 million patients with chronic hepatitis B infection in the world. A considerable number of the chronic cases progress to liver cirrosis and liver tumours. In some cases the hepatitis infections also take a rapid and severe course as in fulminant B hepatitis with about 90% mortality. At present there is no known effective treatment against hepatitis B infections. The replication of hepatitis B virus is similar to that of retrovirus and it contains the same essential viral reverse transcriptase
REFERENCES:
patent: 3817982 (1974-06-01), Verhevden et al.
Acton et al., "Improved Antitumor Effects in 3'-Branched Homologs of 2'-Deoxythioguanosine, Synthesis and Evaluation of Thioguanine Nucleosides of 2,3-Dideoxy-3-(hydroxymethyl-D-erythro-pentofuranose," J. Medicinal Chem., 22(5), 518-525 (1979).
Shuto et al., "Chemical Conversion of Uridine to 3'-Branched Sugar Nucleosides (Nucleosides and Nucleotides. 42)," Nucleosides & Nucleotides, 1, 263-273 (1982).
Suemune et al., "Enzymatic Procedure for the Synthesis of Prostaglandin A.sub.2, " Chem. Pharm. Bull., 36(1), 15-21 (1988).
Okabe et al., "Synthesis of DiDeoxynucleosides ddC and CNT from Glutamic Acid, Ribonolactone, and Pryimidine Bases," J. Org. Chem., 54(20), 4780-4786 (1988).
Chong et al., "Facile Preparation of (2R, 3S)-and (2S,3R)-3-([[(4-Bromobenzyl)oxy]methyl]oxirane-2-methanol via Asymmetric Epoxidation," J. Org. Chem., 52(12), 2596-2598 (1987).
Classon Bjorn O.
Kvarnstrom Imgemar S.
Samuelsson Bengt B.
Svansson Lars G.
Svensson Stefan C. T.
Crane L. Eric
Medivir AB
Robinson Douglas W.
LandOfFree
Synthesis of furanosyl compounds useful as intermediates in prep does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of furanosyl compounds useful as intermediates in prep, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of furanosyl compounds useful as intermediates in prep will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1375023